Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(17%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_2
1
17%
Ph early_phase_1
1
17%
Ph not_applicable
3
50%
Ph phase_1
1
17%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
N/ANon-phased studies
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
unknown1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (16.7%)
Phase 11 (16.7%)
Phase 21 (16.7%)
N/A3 (50.0%)

Trials by Status

unknown117%
withdrawn117%
active_not_recruiting117%
completed350%

Recent Activity

1 active trials
Showing 5 of 6
active_not_recruitingnot_applicable

Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer

NCT02722525
completedphase_2

18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy

NCT01991977
completedearly_phase_1

18F-DOPA-PET in Planning Surgery in Patients With Gliomas

NCT02020720
completedphase_1

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT00662506
unknownnot_applicable

Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors

NCT02526511
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02722525Not Applicable

Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer

Active Not Recruiting
NCT01991977Phase 2

18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy

Completed
NCT02020720Early Phase 1

18F-DOPA-PET in Planning Surgery in Patients With Gliomas

Completed
NCT00662506Phase 1

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Completed
NCT02526511Not Applicable

Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors

Unknown
NCT02590497Not Applicable

Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
6